GSA Capital Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

GSA Capital Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,040	Closed	-$314K	–	2070
2025 Q4	$314K	Sell	3,040 -4,843	-61%	-$471K	0.03%	1144
2025 Q3	$712K	Buy	7,883 +5,373	+214%	+$471K	0.06%	612
2025 Q2	$221K	Sell	2,510 -341	-12%	-$29.6K	0.02%	1458
2025 Q1	$260K	Sell	2,851 -231	-7%	-$20.8K	0.02%	1248
2024 Q4	$266K	Buy	+3,082	New	+$279K	0.02%	1267
2024 Q3	–	Sell	-13,316	Closed	-$1.22M	–	1925
2024 Q2	$1.22M	Sell	13,316 -5,293	-28%	-$473K	0.09%	378
2024 Q1	$1.69M	Buy	18,609 +8,744	+89%	+$766K	0.13%	173
2023 Q4	$803K	Sell	9,865 -3,345	-25%	-$262K	0.07%	508
2023 Q3	$1.05M	Buy	13,210 +1,480	+13%	+$119K	0.09%	365
2023 Q2	$924K	Buy	11,730 +2,886	+33%	+$226K	0.09%	358
2023 Q1	$687K	Buy	+8,844	New	+$682K	0.07%	518

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $16B AUM 37.57% 1-Year Est. Return

ERSOT

Employees Retirement System of Texas Austin, Texas $12.6B AUM 31.26% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

GSA Capital Partners's PPH Position: Q1 2026 in Review

GSA Capital Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2026, closing a stake of 3,040 shares — an estimated $314K sold.

GSA Capital Partners first reported a position in PPH in Q1 2023 and held it in 11 quarters. The position peaked at $1.69M in Q1 2024. 148 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

GSA Capital Partners reported no remaining VanEck Pharmaceutical ETF position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 3,040 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $314K.
GSA Capital Partners first reported a position in VanEck Pharmaceutical ETF in Q1 2023 and held it in 11 quarters.
GSA Capital Partners's VanEck Pharmaceutical ETF position peaked at $1.69M in Q1 2024.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.